Back to Search
Start Over
Nanobodies as probes to investigate purinergic signaling
- Source :
- Biochemical Pharmacology. 187:114394
- Publication Year :
- 2021
- Publisher :
- Elsevier BV, 2021.
-
Abstract
- Nanobodies (VHHs) are the single variable immunoglobulin domains of heavy chain antibodies (hcAbs) that naturally occur in alpacas and other camelids. The two variable domains of conventional antibodies typically interact via a hydrophobic interface. In contrast, the corresponding surface area of nanobodies is hydrophilic, rendering these single immunoglobulin domains highly soluble, robust to harsh environments, and exceptionally easy to format into bispecific reagents. In homage to Geoffrey Burnstock, the pioneer of purinergic signaling, we provide a brief history of nanobody-mediated modulation of purinergic signaling, using our nanobodies targeting P2X7 and the NAD+-metabolizing ecto-enzymes CD38 and ARTC2.2 as examples.
- Subjects :
- 0301 basic medicine
Single variable
Purinergic Antagonists
Immunoglobulin domain
CD38
Biochemistry
03 medical and health sciences
0302 clinical medicine
Animals
Humans
Amino Acid Sequence
Pharmacology
Heavy chain
biology
Chemistry
Receptors, Purinergic
Single-Domain Antibodies
Purinergic signalling
Protein Structure, Tertiary
Cell biology
Antisense Elements (Genetics)
030104 developmental biology
Purinergic Agonists
030220 oncology & carcinogenesis
ADP-ribosylation
biology.protein
Antibody
Immunoglobulin Heavy Chains
Signal Transduction
Subjects
Details
- ISSN :
- 00062952
- Volume :
- 187
- Database :
- OpenAIRE
- Journal :
- Biochemical Pharmacology
- Accession number :
- edsair.doi.dedup.....fab2385e130b14143c4f08b1e7ed73de
- Full Text :
- https://doi.org/10.1016/j.bcp.2020.114394